Join us virtually at JPM26

‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

No images? Click here

Endpoints at JPM26: Biopharma's Foundational Reset

Can biopharma win the AI talent war?

JANUARY 12 - 13, 2026 | 7:00 AM - 5:00 PM PT
VIRTUAL + SAN FRANCISCO

Biopharma has an AI problem, and it's not about the technology.

The industry has embraced AI as critical to its future, but big tech is winning the war for the people who actually know how to build it. Join our session as VZVC's Vijay Pande and Bausch + Lomb's Brent Saunders sit down with Drew Armstrong to address what no one wants to admit: biopharma is losing the talent war. Can the biopharma really compete — or is it about to get left behind?

CHOOSE YOUR PASS

All in-person passes include access to the Endpoints Hub.

ALL-ACCESS

Join us in-person on Monday & Tuesday  

DAY PASS

Join us in-person on Monday or Tuesday  

VIRTUAL PASS

Join us virtually (free)  

FEATURED SESSION

Robert Nelsen isn't known for holding back. The ARCH Venture Partners co-founder has been one of biotech's most vocal and successful investors, and he's sitting down with Endpoints to share an unfiltered take on the biggest disruptions facing the industry — from AI's real impact to the China question, and what both mean for the year ahead. 

View the full agenda here.

Robert Nelsen

Robert Nelsen
Co-founder & Managing Director
ARCH Venture Partners

Charting biotech's course for 2026

Catalent CEO Alessandro Maselli and John Carroll return for their annual predictions session, charting what's ahead for biotech in 2026. Last year, Carroll took heat for his bullish M&A forecast — until the second half proved him right with a string of blockbuster deals. This year, they're tackling everything from manufacturing pressures to funding dynamics and what the dealmaking momentum really means for the months ahead.

NEW: In-person passes include access to our invite-only networking reception, featuring a live taping of Post-Hoc Live and special guest Noubar Afeyan, Founder and CEO of Flagship Pioneering.

These conversations will set your agenda for navigating what's in store for next year. Join us. 

RESERVE YOUR SPOT

Virtual passes are available at no charge
Going to San Francisco? In-person tickets available

EVENT SPONSORS

Vir Biotechnology
 
Catalent
 
FUJIFILM Biotechnologies
Biocon Biologics
pwc
Tarsus Pharmaceuticals
Foundation Medicine
GILEAD
Slalom and Salesforce
 
Cencora
CSL
Prolific Machines
Otsuka Pharmaceutical Co.
 
Novotech